STTK
Shattuck Labs, Inc.
$4.94
+0.76
(+18.18%)
Mkt Cap
236.64M
Volume
1,288,298
52W Range
0.712-8.33
Sector
Healthcare
Beta
1.09
EPS (TTM)
-0.63
P/E Ratio
-5.20
Revenue (TTM)
1.00M
Rev Growth (5Y)
-36.8%
EPS Growth (5Y)
N/A
Company Description
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.72M | 1.66M | 652,000 | 30.02M | 9.93M | 9.89M | 22.44M |
| Net Income | (48.81M) | (75.41M) | (87.30M) | (101.94M) | (44.97M) | (36.60M) | (23.98M) | (7.39M) |
| EPS | -0.70 | -1.49 | -2.05 | -2.41 | -1.07 | -0.88 | -0.57 | -0.49 |
| Free Cash Flow | (39.95M) | (60.57M) | (81.64M) | (106.11M) | (65.04M) | (34.39M) | (21.45M) | (8.08M) |
| FCF / Share | -0.57 | -1.19 | -1.92 | -2.50 | -1.55 | -0.82 | -0.51 | -0.54 |
| Operating CF | (39.88M) | (60.52M) | (81.23M) | (94.50M) | (57.12M) | (33.66M) | (20.98M) | (6.90M) |
| Total Assets | 91.03M | 91.05M | 159.56M | 205.32M | 298.58M | 348.99M | 44.97M | 68.16M |
| Total Debt | 1.58M | 3.41M | 4.20M | 4.90M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 54.19M | 57.39M | 125.63M | 47.38M | 92.27M | 157.90M | 7.01M | 31.64M |
| Book Value | 82.39M | 79.63M | 144.71M | 176.16M | 271.79M | 309.86M | (34.55M) | (11.08M) |
| Return on Equity | -0.59 | -0.95 | -0.60 | -0.58 | -0.17 | -0.12 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.00M | 0 | 0 | 0 | 3.00M | 1.61M | 1.11M | 714,000 | 686,000 | 200,000 |
| Net Income | (14.77M) | (12.59M) | (10.06M) | (12.46M) | (13.70M) | (18.68M) | (16.68M) | (21.55M) | (18.50M) | (17.69M) | (27.54M) | (21.35M) |
| EPS | -0.13 | -0.12 | -0.14 | -0.24 | -0.27 | -0.37 | -0.33 | -0.42 | -0.37 | -0.41 | -0.65 | -0.50 |
| Free Cash Flow | (13.36M) | (8.49M) | (9.00M) | (10.43M) | (12.03M) | (17.37M) | (16.11M) | (10.94M) | (16.16M) | (19.44M) | (16.75M) | (18.91M) |
| FCF / Share | -0.12 | -0.08 | -0.12 | -0.20 | -0.24 | -0.34 | -0.32 | -0.22 | -0.32 | -0.45 | -0.39 | -0.45 |
| Operating CF | (13.42M) | (8.49M) | (8.93M) | (10.43M) | (12.03M) | (17.37M) | (16.07M) | (10.92M) | (16.16M) | (19.42M) | (16.73M) | (18.62M) |
| Total Assets | 102.12M | 91.03M | 100.33M | 64.37M | 77.17M | 91.05M | 111.72M | 128.61M | 146.34M | 159.56M | 130.46M | 155.27M |
| Total Debt | 2.04M | 1.58M | 1.76M | 2.97M | 3.19M | 3.41M | 3.62M | 3.82M | 4.01M | 4.20M | 4.39M | 4.57M |
| Cash & Equiv | 90.42M | 54.19M | 42.55M | 50.47M | 60.90M | 57.39M | 43.83M | 60.69M | 76.00M | 125.63M | 40.63M | 71.89M |
| Book Value | 95.83M | 82.39M | 93.24M | 57.02M | 67.59M | 79.63M | 96.58M | 110.62M | 128.81M | 144.71M | 112.78M | 138.46M |
| Return on Equity | -0.15 | -0.15 | -0.11 | -0.22 | -0.20 | -0.23 | -0.17 | -0.19 | -0.14 | -0.12 | -0.24 | -0.15 |
STTK News
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs, Inc. Announces Proposed Public Offering
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Why Is Shattuck Labs Stock Trading Lower On Monday?
Shattuck Labs Announces Phase 1 Results for SL-325
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Aberdeen Group plc Buys 436,673 Shares of Shattuck Labs, Inc. $STTK
Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.50